Pardis Sabeti received the 2017 National Academy of Sciences Richard Lounsbery Award in biology for her groundbreaking work in computational genetics and global health. A professor at Harvard University, the Broad Institute, and the Howard Hughes Medical Institute, Sabeti has developed computational methods to detect genetic variants under natural selection, and has applied these methods to both humans and pathogens. She has conducted pioneering genomic analyses of Ebola and Lassa viruses, and her work played an important role in tracking Ebola transmission during the 2014 outbreak in West Africa. Sabeti recently spoke with PNAS about her efforts to combat emerging diseases.
PNAS: How did you first get interested in computational genetics?
Sabeti: I've always really liked math and solving puzzles with math. I really enjoyed my math courses in college at MIT [Massachusetts Institute of Technology], but I also wanted to impact human health. Genetics really struck me because it is biology as mathematical information. So it had all of the components of what I wanted to do.
PNAS:
What have been some of the key applications of the computational methods you developed to detect genetic variants under evolutionary selection in humans and in pathogens?
Sabeti:
In my graduate studies I really became interested in how we can mine data from the human genome and find footprints of ancient evolutionary adaption both in humans and in pathogens (1-3). Essentially, if a variant is important for the survival or reproductive success of an organism, it will be likely to be passed on to that person's children and to their children's children, and as a result it will spread in the population. I developed computational methods that allow you to find the footprints of ancient evolutionary pressure and then used them to pinpoint specific mutations that have an important biological impact. The key application of these kinds of methods is to find those functional variations that are important for the survival of humans or the microbes that infect humans. These methods have been used to track down variations in humans that are important in resistance to infectious diseases, such as malaria. Interestingly, we can also apply these same tools to track drug resistance in malaria and really understand how the malaria parasites are changing to survive against our immune system and the drug pressures we put on them.
PNAS:
In 2014 you published a landmark Science article on the human-to-human transmission of the Ebola virus (4). How did that article come about, and what was its significance?
Sabeti: In 2014 our group was working with our collaborators in Sierra Leone and in Nigeria on a disease called Lassa fever, which is a hemorrhagic fever virus much like Ebola. We had gotten a grant to set up surveillance in West Africa for infectious diseases. Startlingly, just at that time the Ebola outbreak was declared in Guinea just across the border, and our collaborators in Sierra Leone found themselves at the epicenter of the outbreak. We were trying to help them rapidly do diagnoses and call attention to the problem. We had developed a number of techniques to sequence Lassa fever over the last few years, and we were able to use them to sequence the Ebola virus and generate the data in a matter of weeks (4) . It showed that we could release this kind of data in real-time, and that we could potentially have an understanding of transmission as well as identifying mutations in the virus that might impact diagnostics and therapies. The fact that we could show with data that the virus was mutating also provided a greater push to move quickly.
How are you continuing to combat pandemics, such as Ebola and Lassa fever?
Sabeti: Over the course of the last few years, we've set up sequencing machines in Sierra Leone, Senegal, and Nigeria, and we've partnered with colleagues in Liberia to help their sequencing efforts there. Every summer we bring someone from each of those countries to receive training in advanced sequencing. We also have about 20 people who are here in summer getting foundational learning in molecular diagnostics for these viruses. We continue to build better diagnostics and an understanding of how these viruses work and of host responses to these viruses.
What has surprised you the most during your research career?
Sabeti: One of the biggest surprises was the discovery that Lassa fever might be important in our history. I was scanning the human genome with the International Haplotype Map project using the test I had developed to try to find footprints of ancient adaptation (5-7). The first time I did this, the strongest signal we found was for a gene that's critical for infection with Lassa virus. It was a really exciting moment, recognizing that actually this virus is circulating in West Africa, where we discovered the signal of selection, and might have been around for a really long time. I think that was a major turning point in my career, so that's probably one of the most meaningful surprises.
PNAS: How have your diverse interests outside of the laboratory (such as being the lead singer of the rock band Thousand Days) influenced your approach to science and research?
Sabeti: I do have a number of passions, music being one of the greatest ones. I often say that people underestimate the creativity that you need in science, and the rigor that you need in music or other creative endeavors. Both require you to be able to start with an exploratory phase, where you discover and think and imagine all of the things that are possible, but then to get that out into the world it takes a large amount of rigor, either to produce a song with 80 tracks all in the right way, or to do all of the right controls and to test a hypothesis carefully. Music is particularly important to me because in West Africa, where we work, music is also really meaningful for them. I sing with my African colleagues and write music with them, and we even recently released an album of music together.
